Evaluation of Hepatitis B Vaccination Coverage and Serological Response in People Living with HIV

Creative Commons License

Üçer S., Gürkaynak P., Gümüş U. E., Altun M. S., Demircan Ş. A., KAYA KILIÇ E., ...Daha Fazla

Duzce Medical Journal, cilt.28, sa.2, ss.207-211, 2026 (ESCI, Scopus, TRDizin)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 28 Sayı: 2
  • Basım Tarihi: 2026
  • Doi Numarası: 10.18678/dtfd.1910893
  • Dergi Adı: Duzce Medical Journal
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, CINAHL, EMBASE, Directory of Open Access Journals, TR DİZİN (ULAKBİM), Academic Search Ultimate (EBSCO), Biomedical Reference Collection: Corporate Edition (EBSCO)
  • Sayfa Sayıları: ss.207-211
  • Anahtar Kelimeler: Hepatitis B vaccines, HIV, antibodies
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Aim: People living with HIV (PLWH) face a heightened risk of acquiring hepatitis B virus (HBV) infection because these two viruses share common transmission pathwa ys. HIV/HBV coinfection is associated with accelerated liver disease progression. Consequently, hepatitis B vaccination is a critical preventive measure for PLWH. This study was designed to assess the serological response to hepatitis B vaccination in PLWH. Material and Methods: PLWH followed at the Infectious Diseases and Clinical Microbiology Clinic who were seronegative for HBsAg, anti-HBs, and anti-HBc IgG were retrospectively identified. Anti-HBs levels measured 1 month to 1 year after the final vaccine dose were assessed. Criteria associated with low response (anti-HBs titer: <100 mIU/mL) and high response (≥100 mIU/mL) were also evaluated. Results: A total of 54 patients were included in the final analysis. The median age was 43 (range, 22–80) years and 25.9% of the patients were female. Forty-nine patients (90.7%) had anti-HBs levels ≥10 mIU/mL. Anti-HBs levels ≥100 mIU/mL were observed in 10 (28.6%) patients who had received at least one double-dose vaccination versus 3 (15.8%) patients who had not (p=0.341), and in 18 (51.4%) patients with undetectable HIV RNA versus 5 (26.3%) patients with detectable HIV RNA (p=0.091), without reaching statistical significance. Conclusion: Adherence to the hepatitis B vaccination schedule was found to be suboptimal. Identifying the underlying causes of poor vaccination adherence and implementing strategies to improve compliance are essential in PLWH.